Pfizer Inc. (PFE) Raised to Buy at Zacks Investment Research


The firm currently has a $34.00 price target on the biopharmaceutical company's stock. Zacks Investment Research 's target price suggests a potential upside of 11.51% from the company's previous close.



from Biotech News